7-Ethylcamptothecin, also known as 7-ethyl-10-hydroxy-camptothecin (SN38), is a potent anticancer agent derived from Camptotheca acuminata that has been shown to possess remarkable activity against various types of cancers including colon, ovarian, and lung cancer. It was first synthesized in 1984 and since then it has been extensively studied for its pharmacological properties.
Top ten keywords from google and synonyms:
7-Ethyl-10-hydroxycamptothecin; 7-Ethyl-10-[(4-formyl-1-piperazinyl)carbonyloxy] camptothecin; 7-ethyl-10-hydroxy-(6aS-cis)-oplopan-3-one-5,6,7,8-tetrahydroindolizine-2,3-dione; CPT-11 active metabolite; SN 38; (S)-(+)-7-Ethyl-10-hydroxycamptothecin; 7-Ethyl-20-deoxy-5-O-demethylepipodophyllotoxin 5-O-(3,4,5-trimethoxybenzoate); (S)-7-Ethyl-10-hydroxycamptothecin
Health benefits of this product:
The primary health benefit of 7-ethylcamptothecin is its strong anticancer properties. It works by inhibiting the activity of topoisomerase I, which is an enzyme involved in DNA replication and cell division. By blocking this enzyme, SN38 prevents cancer cells from dividing and multiplying, leading to their death.
In addition to its anticancer effects, 7-ethylcamptothecin has been shown to exhibit other potential therapeutic effects such as:
Anti-inflammatory: SN38 has been shown to possess anti-inflammatory properties by inhibiting the production of pro-inflammatory cytokines.
Neuroprotective: Studies have suggested that SN38 may have neuroprotective effects and could be useful in the treatment of neurodegenerative disorders such as Alzheimer's disease.
Anti-viral: SN38 has been shown to inhibit the replication of certain viruses, including HIV and herpes simplex virus.
The primary mechanism of action of 7-ethylcamptothecin is the inhibition of topoisomerase I. This enzyme is essential for DNA replication and transcription, and SN38 binds to it, preventing it from unwinding the DNA double helix. As a result, the DNA becomes damaged and the cancer cells cannot divide or multiply, ultimately leading to their death.
7-ethylcamptothecin is a potent cytotoxic agent and therefore can cause serious side effects. It should only be used under the supervision of a qualified healthcare professional. Patients taking SN38 may experience nausea, vomiting, diarrhea, fatigue, and low white blood cell count.
The common side effects of 7-ethylcamptothecin include:
The dosing of 7-ethylcamptothecin varies depending on the type of cancer being treated and the individual patient. It is usually administered intravenously by a healthcare professional.
7-Ethylcamptothecin is a potent anticancer agent that has shown remarkable activity against various types of cancers. It works by inhibiting the activity of topoisomerase I, which is an enzyme involved in DNA replication and cell division. In addition to its anticancer effects, SN38 has been shown to exhibit potential therapeutic effects such as anti-inflammatory, neuroprotective, and anti-viral properties. However, due to its cytotoxicity, it should only be used under the supervision of a qualified healthcare professional.